Key Takeaway: Olema Oncology has reported its financial and operational results for the second quarter of 2026. The company has completed enrollment in the pivotal Phase 3 OPERA-01 trial, with top-line data anticipated in early 2027. Additionally, initial Phase 1 clinical data for OP-3136 was presented at the 2026 ASCO Annual Meeting, and a collaboration with Bayer has been established.
Market Sentiment Analysis
POSITIVE FACTORS
Completed enrollment in the pivotal Phase 3 OPERA-01 trial.
Top-line data expected in the first quarter of 2027.
Presented initial Phase 1 clinical data at the 2026 ASCO Annual Meeting.
Announced collaboration with Bayer for clinical trial evaluation.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+73%
120-day peak, hindsight
Typical move
8.6%
average across 6 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
Palazestrant
Phase 3 · Breast Cancer
Full Press Release Details
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a clinical trial collaboration and supply agreement with Bayer to evaluate
Frequently Asked Questions
What are the key results from Olema's Q2 2026 report?
Olema completed enrollment in the Phase 3 OPERA-01 trial and presented Phase 1 data for OP-3136.
When is the top-line data for OPERA-01 expected?
Top-line data for the OPERA-01 trial is expected in the first quarter of 2027.
What collaboration did Olema announce?
Olema announced a clinical trial collaboration and supply agreement with Bayer.
Where was the initial Phase 1 data presented?
The initial Phase 1 clinical data for OP-3136 was presented at the 2026 ASCO Annual Meeting.